Shares of obesity drug developers were volatile this week amid good news for Eli Lilly's (LLY) drug candidate orforglipron, ...

March 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate ...

Meeting to be held in Boston on April 9 and in New York on April 10 hosted by Piper Sandler.Stay Ahead of the Market: Discover outperforming ...

HC Wainwright reaffirmed their buy rating on shares of Altimmune (NASDAQ:ALT – Free Report) in a research report sent to ...

Altimmune's stock, which was added to the Nasdaq Biotechnology Index (NBI) in December, has a short interest of 28.2%, ...

In the last three months, 8 analysts have published ratings on Altimmune (NASDAQ:ALT), offering a diverse range of perspectives from bullish to bearish. The table below provides a concise overview ...

The last time I wrote an article on Altimmune, Inc. (NASDAQ:ALT) it was in a Seeking Alpha article entitled "Altimmune: Pemvidutide As MASH Drug Could Provide Competitive Edge." In this article ...

In this article, we will see how Altimmune, Inc. (NASDAQ:ALT) compares to the other top short squeeze stocks that have received a Buy rating from analysts. Stock market trading has an ever ...

Claim your 7-day free trial now. Altimmune Inc ALT hosted a virtual R&D day on Thursday, marking the first disclosure of Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) as potential ...

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune ...